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Attenuation of NADPH Oxidase Activation and Glomerular
Filtration Barrier Remodeling With Statin Treatment
Adam Whaley-Connell, Javad Habibi, Ravi Nistala, Shawna A. Cooper, Poorna R. Karuparthi,
Melvin R. Hayden, Nathan Rehmer, Vincent G. DeMarco, Bradley T. Andresen,
Yongzhong Wei, Carlos Ferrario, James R. Sowers
Abstract—Activation of reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase by angiotensin II is
integral to the formation of oxidative stress in the vasculature and the kidney. 3-Hydroxy-3-methylglutaryl-coenzyme
A reductase inhibition is associated with reductions of oxidative stress in the vasculature and kidney and associated
decreases in albuminuria. Effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibition on oxidative stress in
the kidney and filtration barrier integrity are poorly understood. To investigate, we used transgenic TG(mRen2)27
(Ren2) rats, which harbor the mouse renin transgene and renin-angiotensin system activation, and an immortalized
murine podocyte cell line. We treated young, male Ren2 and Sprague-Dawley rats with rosuvastatin (20 mg/kg IP) or
placebo for 21 days. Compared with controls, we observed increases in systolic blood pressure, albuminuria, renal
NADPH oxidase activity, and 3-nitrotryosine staining, with reductions in the rosuvastatin-treated Ren2. Structural
changes on light and transmission electron microscopy, consistent with periarteriolar fibrosis and podocyte foot-process
effacement, were attenuated with statin treatment. Nephrin expression was diminished in the Ren2 kidney and trended
to normalize with statin treatment. Angiotensin II–dependent increases in podocyte NADPH oxidase activity and
subunit expression (NOX2, NOX4, Rac, and p22phox) and reactive oxygen species generation were decreased after in
vitro statin treatment. These data support a role for increased NADPH oxidase activity and subunit expression with
resultant reactive oxygen species formation in the kidney and podocyte. Furthermore, statin attenuation of NADPH
oxidase activation and reactive oxygen species formation in the kidney/podocyte seems to play roles in the abrogation of
oxidative stress-induced filtration barrier injury and consequent albuminuria. (Hypertension. 2008;51[part 2]:474-480.)
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Renin-angiotensin system (RAS) activation and subse-quently elevated angiotensin II (Ang II) exert the pres-
sor, proliferative, profibrotic, and proinflammatory actions.1–3
Activation of tissue reduced nicotinamide-adenine dinucleo-
tide phosphate (NADPH) oxidase seems to contribute to
deleterious actions, such as oxidative stress and endothelial
dysfunction manifesting as hypertension, albuminuria, and
progressive glomerular dysfunction, that may ultimately lead
to chronic kidney disease.1,4 There is accumulating evidence
that tissue-based RAS further modulates cell growth, metab-
olism, and tissue remodeling.5,6
Evidence for a local RAS in the glomerulus raises the
prospect of NADPH oxidase–induced podocyte and filtration
barrier injury.7,8 Furthermore, in vitro protein exposure,
mechanical stretch, and glomerular hypertension enhance
tissue Ang II production, which may potentiate the impact of
elevated blood pressure on glomerular injury manifesting as
albuminuria.9,10 Previous work related to the pathogenesis of
albuminuria delineated abnormalities such as basement mem-
brane thickening, loss of the slit-pore diaphragm integrity,
and widening of the podocyte foot process base width.11
Recent evidence characterized foot process effacement and
loss of the slit-pore diaphragm as critical in decreasing
filtration barrier integrity.12
3-Hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA)
reductase inhibitors (statins) exert beneficial actions on oxi-
dative stress and endothelial dysfunction independent of their
cholesterol-lowering properties. Many of the actions of st-
atins are thought to be mediated by decreasing reactive
oxygen species (ROS) formation in various tissues.13 ROS
derived from NADPH oxidase activation have been shown to
play a critical role in hypertrophy, fibrosis, and remodeling in
the heart and vasculature.14–16 NADPH oxidase is a multi-
component enzyme complex that is composed of the
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membrane-bound heterodimer gp91phox (phox indicates
phagocytic oxidase; NOX2) and its homologue NOX4;
p22phox; the cytosolic regulatory subunits p40phox, p47phox, and
p67phox; and the small GTP-binding protein, Rac1.14,15 Statins
reduce cellular levels of isoprenoids and inhibit the subse-
quent isoprenylation of small G proteins such as Rac.17,18
Accordingly, we evaluated the impact of statin treatment
on increases in NADPH oxidase activity and contemporane-
ously on the glomerular filtration barrier and podocyte
integrity. We used the transgenic TG(mRen2)27 (Ren2) rat
with the mouse renin transgene and RAS activation, as well
as an immortalized murine podocyte cell line. We hypothe-
sized that Ang II stimulation of NADPH oxidase would
contribute to glomerular filtration barrier remodeling and the
podocyte generation of ROS. We further hypothesized that
the beneficial effects of statin therapy would be mediated in
part through reductions in NADPH oxidase activation and
generation of ROS.
Materials and Methods
Animals and Treatments
All of the animal procedures were approved by the institutional
animal care and use committees at the University of Missouri Harry
S. Truman Veterans’ Affairs Medical Center and housed in accor-
dance with National Institutes of Health guidelines. Ren2 (5- to
6-week–old) and age-matched Sprague-Dawley (SD) male rats were
randomly assigned to placebo-treated control (Ren2-C and SD-C,
respectively; n6 each) or rosuvastatin (AstraZeneca) treatment
groups (Ren2-RSV and SD-RSV, respectively; n4 each). Rosuv-
astatin (20 mg/kg per day) in saline or an equal volume of saline was
administered intraperitoneally to the rosuvastatin or control groups,
respectively, for 21 days.
Systolic Blood Pressure and Albuminuria
Details of systolic blood pressure (SBP) and albuminuria are available in
a data supplement available online at http://hyper.ahajournals.org.
Briefly, SBP was determined at the end of rosuvastatin treatment on
days 19 or 20 using the tail cuff after acclimatization and restraint
conditioning for 48 hours on each group of rats (SDC, n6;
SD-RSV, n4; Ren2-C, n6; Ren2-RSV, n4).12–16 In addition,
albuminuria from each group of rats (SDC, n6; SD-RSV, n4;
Ren2-C, N6; Ren2-RSV, n4) was determined at the beginning,
middle, and end of treatment.12
Transmission Electron Microscopy Methods
Details of the transmission electron microscopy (TEM) in this study
are available in the data supplement. Briefly, kidney cortical tissue
from each group of rats (SDC, n6; SD-RSV, n4; Ren2-C, n6;
Ren2-RSV, n4) was prepared as described previously,12,14,19 and 3
glomeruli per rat were evaluated with five 10-k and 60-k images per
glomeruli. Five measurements were performed for each variable per
image, including basement membrane thickness, slit pore diameter
and number per 100 m, and foot-process base width.
Immunofluorescent Studies
Details of the immunofluorescent studies are available in the data
supplement. Briefly, harvested kidney cortical tissue from each
group of rats (SDC, n4; SD-RSV, n4; Ren2-C, n4; Ren2-RSV,
n4) was prepared13–16 and evaluated for nephrin C-17, gp91phox
(NOX2), and Rac1 antibody, as well as to assess 3-nitrotyrosine
content, a marker for peroxynitrite formation.13–15
Western Blot Analysis
Details of the Western blot analysis are available in the data
supplement. Briefly, kidney cortical tissue from each group of rats
(SDC, n4; SD-RSV, n4; Ren2-C, n4; Ren2-RSV, n4) was
used to evaluate nephrin with 2 antibodies (N-20 and C-17); total
protein was stained with amido-black staining to normalize the data.
Measurement of NADPH Oxidase Activity
NADPH oxidase activity was determined in plasma membrane
fractions from each group of rats (SDC, n6; SD-RSV, n4;
Ren2-C, n6; Ren2-RSV, n4) and podocyte cell lysates.15–17
Light Microscopy
Harvested kidney cortical tissue from each group of rats (SDC, n4;
SD-RSV, n4; Ren2-C, n4; Ren2-RSV, n4) were stained with
Verhoeff-van Gieson, which is specific for fibrosis and stains elastin
(black), nuclei (blue black), collagen (red), and connective tissue
(yellow).14,15,19
Podocyte Cell Culture
Details of cell culture are available in the data supplement. Briefly,
a dose-response curve was established for Ang II stimulation of
NADPH oxidase activity in podocyte cell lysates using a time-
dependency assay, and rosuvastatin inhibition was based on previous
experiments.17 In addition, superoxide generation in podocyte cell
lysates was evaluated using oxidative fluorescent dihydroethidium
staining.17
RNA Extraction and Subunit Expression by
Real-Time PCR
Details of the determination of RNA extraction from podocyte cell
lysates are available in the data supplement. RNA was extracted
from podocytes using RNeasy Mini kits (Qiagen), and 100 ng of
starting cDNA was used for Real-Time PCR with the following
primers: p22phox and NOX4, gp91phox (NOX2; 5-CCA ACT GGG
ATA ACG AGT trichloroacetic acid (TCA)-3) and reverse (5-
GAG AGT TTC AGC CAA GGC TTC-3) and Rac1.20 Expression
levels were normalized using 18S as the control.
Statistical Analysis
All of the values are expressed as meanSE. Statistical analyses
were performed in SPSS 13.0 (SPSS Inc) using ANOVA with
Fisher’s least significant difference as appropriate and Student’s t
test for paired analysis. Significance was accepted as P0.05.
Results
Effect of Rosuvastatin on SBP and Albuminuria
As measured at the end of the treatment period, there were
increases in SBP in Ren2 (207.41.3 mm Hg) when com-
pared with SD controls (156.09.8 mm Hg; P0.05) without
reductions in rosuvastatin-treated animals (2024.5 mm Hg
and 159.79.7 mm Hg, respectively; Figure 1A). Albumin-
uria was increased in the Ren2 rats at 5 weeks (0.150.05
mg/mg), 7 to 8 weeks (0.330.05 mg/mg), and significantly
at 9 weeks (0.470.08 mg/mg; P0.05) when compared
with SD controls at 5 weeks (0.120.02 mg/mg), 7 to 8
weeks (0.140.04 mg/mg), and 9 weeks (0.110.01 mg/mg;
Figure 1B). There were improvements in the rosuvastatin-
treated Ren2 rats at 5 weeks (0.170.03 mg/mg), 7 to 8
weeks (0.180.04 mg/mg), and significantly at 9 weeks
(0.260.04 mg/mg; P0.05).
Effect of Rosuvastatin on Glomerular Remodeling
Glomerular filtration barrier structural integrity was mea-
sured by TEM and light microscopy with Verhoeff-van
Gieson and nephrin immunostaining. TEM images at 10 000
and 60 000 (Figure 2A) were used to evaluate 4 criteria for
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filtration barrier integrity as described above. Significant
changes in all 4 of the variables were observed when
comparing Ren2 to SD glomeruli, and these changes were
attenuated with rosuvastatin treatment (Figure 2B).
There were fewer slit-pores in Ren2 rats (4.30.2 slit
pores/100 m; P0.05) versus SD control rats (5.00.1 slit
pores/100 m), improved with rosuvastatin treatment in Ren2
and SD rats (5.10.1 and 5.80.1 slit pores per 100 m,
respectively; each P0.05; Figure 2B). Similarly, slit-pore
diameter was less in Ren2 glomeruli (25.01.5 nm) than in
SD (34.31.3 nm; P0.05). However, rosuvastatin treatment
did not improve slit-pore diameter in the Ren2 or SD rats
(23.91.9 nm and 29.32.5 nm, respectively; each P0.05).
Increases in podocyte foot process base width paralleled the
loss of the slit-pore number and diameter in the Ren2 rats
(208.29.7 nm) when compared with SD controls
(159.65.5 nm) that improved with rosuvastatin treatment in
both Ren2 and SD rats (140.64.9 nm and 131.85.7 nm,
respectively; each P0.05). Interestingly, basement mem-
brane thickness was not greater in the Ren2 (98.71.9 nm)
when compared with SD (95.32.6 nm) glomeruli (P0.05),
with no rosuvastatin treatment effect in either Ren2 or SD rats
(102.62.9 nm and 99.95.9 nm; each P0.05).
Figure 1. SBP and albuminuria in transgenic Ren2 rats. A, SBP
in Ren2 rats at the end of treatment period. B, Albuminuria in
the Ren2 rat as measured at the beginning of treatment (6
weeks of age or 0 weeks of treatment), middle of treatment
period (7 to 8 weeks of age or 1.5 weeks of treatment), and end
of treatment period (9 weeks of age or 3 weeks of treatment).
*P0.05 vs age-matched SD-C (n6); #P0.05 when Ren2-C
(n6) 3 week is compared with 0 weeks; **P0.05 when Ren2-
RSVs (n4) are compared with age-matched SD-C rats.
Figure 2. Rosuvastatin improves indices of podocyte foot-process effacement on TEM. A, Representative TEM images at 10 000 (left
panel) and 60 000 (right panel). B, Indices for glomerular filtration barrier integrity. *P0.05 when Ren2-Cs (n6) are compared with
age-matched SD-Cs (n6); **P0.05 when Ren2-RSVs (n4) or SD-RSVs (n4) are compared with age-matched controls.
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There were attendant decreases in nephrin by immuno-
staining and Western analysis in the Ren2 rats (19.51.6
average grayscale intensities; 0.240.07 arbitrary units)
when compared with SD controls (27.94.5 average gray-
scale intensities; 0.4310.090 arbitrary units; each P0.05)
with a trend to improvement in the rosuvastatin-treated Ren2
rats (21.73.6 average grayscale intensities and 0.320.04;
each P0.05; Figure S1A through S1E).
To evaluate the effects of rosuvastatin on glomerular
remodeling, we morphometrically evaluated periarteriolar
fibrosis in Verhoeff-van Gieson–stained sections of the kid-
ney. There was substantial periarteriolar fibrosis in the
adventitia of Ren2 rats (0.650.01% area fibrosis) when
compared with SD controls (0.390.01% area fibrosis;
P0.05) that was improved in the rosuvastatin-treated Ren2
rats (0.410.01% area fibrosis; P0.05; Figure S2A and
S2B). Interestingly, there were decreases in the percent area
in the media of the Ren2 rats (0.280.01% area) compared
with SD controls (0.450.01% area; P0.05), which im-
proved in the rosuvastatin-treated Ren2 rats (0.470.01%
area; P0.05).
Effect of Ang II and Rosuvastatin on NADPH
Oxidase Activity and Subunits
There were expected increases in NADPH oxidase activity in
the Ren2 controls (80.90.1 mOD/mg per minute) when
compared with SD controls (67.90.2 mOD/mg per minute;
P0.05) that improved with rosuvastatin treatment in the
Ren2 rats (57.10.1 mOD/mg per minute; P0.05; Figure
3A). Similarly, there were dose-dependent increases in Ang II
stimulation of NADPH oxidase activity in podocytes with a
maximum occurring at 10 nm (Figure 4A). The increase in
NADPH oxidase activity induced with 10 nM of Ang II
(1.150.03 mOD/mg per minute; P0.05) was completely
prevented with rosuvastatin treatment (0.940.04 mOD/mg
per minute; P0.05; Figure 4B).
Similar to enzyme activity, there were increases in
NADPH oxidase subunits in the kidney cortex of the Ren2
rats and in podocytes. There were increases in NOX2 and Rac
in the Ren2 rats (23.51.4 and 54.910.9 average grayscale
intensities, respectively; each P0.05) compared with SD
controls (19.61.5 and 31.73.6 average grayscale intensi-
ties, respectively; each P0.05) improved with rosuvastatin
treatment (18.12.1 and 27.24.0 average grayscale inten-
sities, respectively; each P0.05; Figure 3B and 3C). Simi-
larly, increases were seen in podocytes with Ang II stimula-
tion of NOX2 and Rac mRNA expression (3.751.30 and
3.340.76 average grayscale intensities, respectively; each
P0.05) relative to controls that were reversed with rosuv-
astatin (0.710.08 and 1.160.30 average grayscale intensi-
ties, respectively; Figure 4D). There were similar increases in
mRNA expression of NOX4 and p22 in podocytes after Ang
II stimulation (3.090.61 and 2.790.68 average grayscale
intensities relative to control, respectively; each P0.05)
reversed with rosuvastatin treatment (1.170.30 and
0.990.23 average grayscale intensities, respectively; each
P0.05; Figure 4D).
Figure 3. Rosuvastatin attenuation of NADPH oxidase in the transgenic Ren2 rat. A, Kidney cortical tissue NADPH oxidase activity in
the Ren2 rat. B, Grayscale intensity measures of NADPH oxidase subunit expression for C. C, Representative images of glomerular
sections immunostained for NADPH oxidase subunits NOX2 and Rac. (scale bar50 mol/L). *P0.05 when Ren2-Cs (n6) are com-
pared with age-matched SD-Cs (n6); **P0.05 when Ren2-RSVs (n4) or SD-RSVs (n4) are compared with age-matched controls.
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Effect of Ang II and Rosuvastatin on Oxidative
Stress Markers
To ascertain whether rosuvastatin affects oxidative stress, we
measured 3-nitrotyrosine as a marker of peroxynitrite forma-
tion in the Ren2 and dihydroethidium in podocytes as a
marker of superoxide anion generation. Kidney tissue nitro-
tyrosine content was increased in the Ren2 (26.31.7 aver-
age grayscale intensities) when compared with SD rats
(12.91.4 average grayscale intensities; P0.05) reversed
with rosuvastatin treatment in the Ren2 rats (15.41.1
average grayscale intensities; P0.05; Figure S3A and S3B).
Similarly, there were increases in superoxide anion genera-
tion after Ang II stimulation (24.54.6 average grayscale
intensities; P0.05) that were reversed with rosuvastatin
(35.44.8 average grayscale intensities; P0.05; Figure S3C
and S3D).
Discussion
This investigation addressed the impact of HMG-CoA reduc-
tase inhibitors (statins) on NADPH oxidase activation and
subunit expression, oxidative stress, and resultant glomerular
filtration barrier and podocyte injury. Filtration barrier/podo-
cyte integrity was evaluated in the transgenic Ren2 rat, an
animal model with the mouse renin transgene and RAS
activation, shown previously to demonstrate enhanced renal
tissue oxidative stress and albuminuria.12,19 Data from the
current investigation indicate that statin therapy has renopro-
tective effects, as demonstrated by reductions in albuminuria,
Figure 4. Rosuvastatin attenuation of Ang II stimulation of NADPH oxidase in podocytes. A, Dose response for Ang II stimulation of
NADPH oxidase activity (n6). B, Rosuvastatin reversal of Ang II stimulation of NADPH oxidase activity (n7). C, Representative immu-
nostaining of NADPH oxidase subunits in podocyte cell culture. D, mRNA expression of NADPH oxidase subunits in podocyte cell cul-
ture. *P0.05 when Ang II was compared with control; for NOX4, Rac1 and p22phox (n14) and NOX2 (n12). **P0.05 when com-
pared with Ang II stimulation alone; each (n8).
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oxidative stress, and improvements in filtration barrier indi-
ces, as well as basement membrane thickening and podocyte
foot process effacement. Findings from this study are consis-
tent with our previous findings in the heart and other reports
that statins decrease NADPH oxidase–related ROS species
generation through inhibition of cytosolic small-molecular-
weight G proteins, such as Rac, and the membrane subunits
of NADPH oxidase.14,18,21
The filtration barrier is composed of endothelium, base-
ment membrane, and visceral epithelial cells called podo-
cytes. Increasing evidence supports podocyte regulation of
various glomerular functions, including basement membrane
turnover, maintenance of the filtration barrier, regulation of
the ultrafiltration coefficient, and mechanical support of the
glomerular tuft.22 Intraglomerular capillaries are continuously
exposed to elevated hydrostatic pressure gradients and are
susceptible to the effects of NADPH oxidase activation and
oxidative stress.21,23 Thus, the findings of periarteriolar and
glomerular fibrosis, in addition to podocyte foot-process
effacement, independent of changes in the basement mem-
brane, in an animal model of NADPH oxidase activation
support a role for ROS-mediated podocyte injury and albu-
minuria. Furthermore, the reductions in fibrosis and foot-
process effacement with in vivo statin therapy suggest a role
for statin reductions in NADPH oxidase and ROS. This
supports the notion that statins may exert a renoprotective
effect in maintaining the integrity of the podocyte and
filtration barrier.
In the present study, the Ren2 rat demonstrated increases in
NADPH oxidase activity, subunit expression, and oxidative
stress in conjunction with podocyte remodeling/effacement
and loss of the slit-pore diaphragm integrity. NADPH oxidase
activation was accompanied by downregulation of nephrin,
an important protein necessary for maintenance of podocyte
slit-pore diaphragm integrity.22–24 The loss of nephrin, in turn,
contributed to effacement of podocytes and loss of integrity
of the slit-pore diaphragm, both requisites for progression of
albuminuria.23–25 Indeed, these changes occurred in the ab-
sence of basement membrane thickening, suggesting the
paramount importance of changes in slit-pore integrity in the
pathogenesis of albuminuria.
In parallel with increased NADPH oxidase activity, there
was an increase in peroxynitrite formation, as measured by
nitrotyrosine staining in Ren2 kidneys, significantly reduced
by statin therapy. NADPH oxidase catalyzes the 1-electron
reduction of molecular oxygen to superoxide anion, which
can react to form short-lived peroxynitrite. Peroxynitrite then
forms stable 3-nitrotyrosine–conjugated molecules.14 Indeed,
nitrotyrosine staining and accompanying fibrosis were partic-
ularly pronounced in the glomerulus. Oxidative stress is a
known stimulus for fibrosis; ROS formation can activate
redox-sensitive transcription factors, such as nuclear factor-
, which promotes collagen and other connective tissue
deposition. The current observation that in vivo statin treat-
ment significantly decreases NADPH oxidase activity and
ROS levels in concert with decreases in albuminuria and
periarteriolar and glomerular fibrosis is the first such report.
Moreover, benefits of rosuvastatin treatment were indepen-
dent of any effects on basement membrane thickness or blood
pressure.
Data in cultured podocyte cells complement our ex vivo
data demonstrating that Ang II stimulates NADPH oxidase
with resultant superoxide anion generation and reversed with
statin treatment. Previous work suggested a role for ATP-
dependent NADPH subunits p22phox, p47phox, p67phox, and
NOX2 in human podocytes.26 Our data further define a role
for NOX4 in the rodent podocyte. NOX4 is a homologue of
NOX2 and has been defined previously in the endothelium,27
and recent immunohistochemical data support a role for
NOX4 in renal mesangial cell injury in db/db diabetic mice.28
Current data further indicate that the NOX4 homologue is a
critical component of the functional membrane NADPH
oxidase enzyme in rodent podocytes and that statin treatment
reduces the expression of this subunit in concert with atten-
uation of podocyte injury.
Perspectives
In summary, data from this investigation support a role for
activation of NADPH oxidase with resultant oxidative stress
and associated loss of glomerular filtration barrier/podocyte
integrity, processes that are reversed with statin treatment,
suggesting a potential renoprotective effect. These salutary
effects of statin treatment in this investigation were mediated
independent of effects on glomerular basement membrane
thickening. However, in interpreting the results of this or any
study that investigates blood pressure–mediated effects, mea-
surement of SBP can be susceptible to large variability
without a time course determination.
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Expanded Methods 
Animals and treatments:  
All animal procedures were approved by the institutional animal care and use 
committees at The University of Missouri, Harry S. Truman VA Medical Center and 
housed in accordance with NIH guidelines. Ren2 (5 to 6 week old) and age-matched SD 
male rats were randomly assigned to placebo treated control (Ren2-C and SD-C, 
respectively) (n=6 each) or rosuvastatin (AstraZeneca) treatment groups (Ren2-RSV and 
SD-RSV) (n=4 each).  Rosuvastatin (20 mg/kg/day) in saline or an equal volume of 
saline was administered in vivo intra-peritoneally (IP) to the rosuvastatin or control 
groups, respectively for 21 days. 
Systolic Blood Pressure (SBP) and Albuminuria: 
SBP was determined at the end of treatment using the tail-cuff method (Harvard 
Systems, Student Oscillometric Recorder) three-times for 10-15 minutes after 
acclimatization and restraint conditioning for 48 hours at the end of treatment on days 19 
or 20 (1-4).  Urine albumin was determined as previously described (1). 
Transmission Electron Microscopy (TEM) Methods: 
Kidney cortical tissue was thinly sliced, placed immediately in primary EM 
fixative, and prepared as previously described (1,3,5).  A JOEL 1200-EX transmission 
microscope was utilized to view all renal samples.  Three glomeruli per rat were 
evaluated with five 10k and 60k images per glomeruli.  TEM images were analyzed using 
ImageJ, (public domain, NIH) and analysis was adapted from previous work (1,3,5,6).  
10k images were used to analyze the number of slit pores per 100 µm of glomerular 
basement membrane.  Straight basement membrane with uniform thickness and upright 
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podocyte foot processes were used to rule out bias sample cuts.  100 µm was calibrated 
using the image legend and randomly placed on a straight glomerular basement 
membrane to measure the number of slit pores.  60k images were used to measure the slit 
pore diameter, the basement membrane thickness and foot process base width.  Five 
measurements were performed for each variable per image.   
Immunofluorescent Studies: 
Harvested kidney cortical tissue was immersed and fixed in 3% paraformaldehyde 
and prepared as previously described (2-4).  Blocks were sectioned and incubated with 
1:100 dilution of primary antibodies in 10 fold diluted blocking agent, and third/fourth 
sections were washed and kept in the blocker.  Over the course of 48 hours, a fifth, sixth, 
and seventh section was incubated with 1:100 nephrin C-17 (Santa Cruz, Santa Cruz, 
CA), 1:100 goat gp91phox (NOX2) (Santa Cruz), 1:100 mouse Rac1 antibody (Upstate 
Cell Signaling) respectively, in 10 fold diluted blocker. Other sections were incubated 
with 1:300 Alexa fluor rabbit anti-goat 647 (Molecular Probe, Eugene, OR) for NOX2, 
goat anti-mouse for Rac, and rabbit anti-goat for Nephrin in 10 fold diluted blocker 
except the sixth, which was stained with 1:300 of Alexa fluor goat anti-mouse 647 for 4 
hours and examined using a laser confocal scanning microscope, images captured by 
using Laser-sharp software (Bio-Rad), and signal intensities measured with MetaVue 
software.  To assess 3-nitrotyrosine content, kidney cortical tissue sections were de-
paraffinized, rehydrated, and epitopes were retrieved in citrate buffer as preciously 
described (2,3,5). 
Western Blot Analysis: 
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Kidney cortical tissue was homogenized using a glass-on-glass Dounce 
homogenizer in sucrose homogenization buffer and centrifuged at 1,000 g to remove 
connective tissue.  Protein concentrations were measured by OPA as above.  60 µg of the 
supernatants were analyzed via SDS-PAGE under reducing conditions on a 7% gel.  The 
protein was transferred to a polyvinylidene difluoride (PVDF) membrane and blocked in 
5% milk in TBST for 30 min.  Two nephrin antibodies (Santa Cruz, N-20 and C-17) were 
used at 1:1000 combined to detect nephrin; an anti-goat HRP linked secondary antibody 
(1:5000) was used to visualize nephrin via film.  The film was scanned into a computer 
and band density was determined using ImageJ.  Total protein was stained with amido-
black staining, which was used to normalize the nephrin data. 
Measurement of NADPH Oxidase Activity:  
NADPH oxidase activity was determined in plasma membrane fractions as 
previously described (3,4,7).   
Light Microscopy:   
Harvested kidney cortical tissue were stained with VVG (Verhoeff-van Gieson); 
which is specific for fibrosis and stains elastin (black), nuclei (blue black), collagen (red), 
and connective tissue (yellow) as previously described (2,3,5).   
Podocyte Cell Culture: 
 Immortalized murine podocyte cells obtained from Peter Mundel, PhD, Mount 
Sinai School of Medicine, were cultured as previously described (7).  A dose response 
curve was established for Ang II stimulation of NADPH oxidase activity using a time 
dependency assay and rosuvastatin inhibition was based on previous experiments (7).  
Preparation and protocols for incubations have been previously described (7).  All 
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cellular assays were normalized to total protein content, determined via Bradford assay.  
Superoxide (02-) generation in podocytes were evaluated by using oxidative fluorescent 
dihydroethidium (DHE) staining as previously described (7).   
RNA extraction and subunit expression by Real-Time PCR: 
Podocytes were grown, differentiated, starved overnight and treated with Ang II 
(10nM) or Ang II + rosuvastatin (10uM) as described above.  RNA was extracted from 
podocytes using RNeasy Mini Kits (Qiagen, Germany). The integrity of extracted RNA 
was assessed visually following separation of samples on a formaldehyde gel.  A ratio of 
2:1 for 28S:18S was considered satisfactory.  In addition, ratios of A260/A280 of 2.0 or 
better indicated samples had minimal protein contamination. Samples were DNase1 
treated with reagents from Invitrogen (Carlsbad, CA) and cDNA prepared using Taqman 
Reverse Transcription Reagents from Applied Biosystems (Foster City, CA). 100ng of 
starting cDNA was used for Real-Time PCR with the following primers: p22phox and 
NOX4, gp91phox (NOX2) (5'-CCA ACT GGG ATA ACG AGT TCA-3') and Reverse (5'-
GAG AGT TTC AGC CAA GGC TTC-3') and Rac1 (8). Universal Real Time cycling 
parameters were used with the following exceptions: annealing temp of 70C for p22phox 
and NOX4, SybrGreen system for p22phox, Nox4, Rac1 and NOX2 and Taqman Universal 
Master Mix for 18S primer/probe set. Expression levels were normalized using 18S as 
control. 18S levels did not change with treatments. In order to account for day-to-day and 
plate-to-plate variations, increases or decreases in transcript level were expressed relative 
to the mean of the SD control group.  Measurements of fold changes were done using 
standard curve method.  
Statistical Analysis: 
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All values are expressed as mean ± standard error.  Statistical analyses were 
performed in SPSS 13.0 (SPSS Inc., Chicago IL) using ANOVA with Fisher’s LSD as 
appropriate and student’s t-test for paired analysis.   Significance was accepted as p<0.05. 
 
Funding: This research was supported by NIH (R01 HL73101-01A1) (JRS) and (P01 
HL-51952) (CF), the Veterans Affairs Merit System (0018) (JRS), and Investigator 
Initiated Grant from AstraZeneca   
 
 
References 
 
1. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer 
CE, Gallagher PE, Tallant EA, Cooper SA, Link CD, Ferrario C, Sowers JR. 
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin 
system in the Ren2 transgenic rat. Am J Physiol Renal Physiol. 2006;291:F1308-
1314. 
2. Habibi J,  Whaley-Connell A , Qazi MA, Hayden MR,  Cooper SA, Stump C, Ferrario 
C, Muniyappa R, Sowers J.  Rosuvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme 
A Reductase Inhibitor, Decreases Cardiac Oxidative Stress and Remodeling in Ren2 
Transgenic Rats.  Endocrinology. 2007;148:2181-2188. 
3. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma 
L, Qazi M, Link D, Karuparthi PR, Stump CS, Ferrario C, Sowers JR,  Angiotensin-II 
Mediated Oxidative Stress Promotes Myocardial Tissue Remodeling in the 
Transgenic TG (mRen2) 27 Ren2 Rat.  Am J Physiol Endocrinol Metab. 
2007;293:E355-E363. 
 at University of Missouri-Columbia on September 14, 2010 hyper.ahajournals.orgDownloaded from 
4.  Wei Y, Whaley-Connell A, Chen K, Habibi J, Uptergrove G, Clark SE, Stump CS,  
Ferrario C, Sowers JR.  Angiotensin II-induced NADPH oxidase activation contribute 
to vascular inflammation, apoptosis and remodeling in hypertensive transgenic Ren2 
rats. Hypertension.  2007;50:384-391. 
5. Hayden MR, Chowdhury N, Cooper S, Whaley-Connell A, Witte L, Wiedmeyer C, 
Stump CS, Ferrario C, Sowers JR.  Mitigation of Proximal Tubuler Actin 
Cytoskeleton Microvilli Remodeling in the TG(mRen2)27 (Ren2) Transgenic Rat 
with AT1 receptor blockade.  Am J of Physiol Renal Physiol. 2007;292:F861-F867. 
6. White KE, Bilous RW. Estimation of podocyte number: a comparison of methods. 
Kidney Int. 2004;66:663-667. 
7. Whaley-Connell A, Morris EM, Rehmer N, Yaghoubian JC, Hayden MR, Habibi J, 
Stump CS, Sowers JR.  Attenuation of Albumin Activation of NAD(P)H Oxidase is 
Mediated via Rac1 Inhibition in Proximal Tubule Cells.  Am J Nephrol. 2007;27:15-
23. 
8. Szöcs K, Lassègue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, 
Quinn MT, Lambeth JD, Griendling KK. Upregulation of Nox-Based NAD(P)H 
Oxidases in Restenosis After Carotid Injury. Arterioscler Thromb Vasc Biol. 
2002;22:21 - 27. 
 
Figure S1:  Decreased Nephrin in Transgenic Ren2 rats.  A) Immunostaining of 
nephrin (C-17) and 4',6-diamidino-2-phenylindole (DAPI).  B)  Fluorescent images from 
panel A were merged with the transmitted images showing the glomerular structure.  C)  
Monostaining of the paraffin embedded kidney sections of different animals which were 
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captured by different system for quantification of nephrin expression in the glomerular 
area of different treatments.  D) Western analysis of nephrin. E) Average gray scale 
intensities measures of panel C, showing significantly smaller number in Ren2C animals. 
(scale bar = 50 µM) *, p <0.05 when Ren2 controls (Ren2-C) (n=4) are compared to age-
matched Sprague-Dawley controls (SD-C) (n=4).   (n=4 for rosuvastatin treated SD and 
Ren2 groups). 
 
Figure S2:  Rosuvastatin attenuation of Peri-Arteriolar Remodeling in the 
Transgenic Ren2 rat. (A) Representative images of Verhoeff-van Gieson (VVG), 
specific for fibrosis, stained sections of arterioles in kidney cortical tissue.  (B)  
Representative images of glomeruli with increases in periglomerular and glomerular 
staining observed in the Ren2 control.  (C) Average calculated values of percentage area 
of adventitia, media and the lumen of the intramural arteries in the heart.  (scale bar=50 
µM)  *, p <0.05 when Ren2 controls (Ren2-C) (n=4) are compared to age-matched 
Sprague-Dawley controls (SD-C) (n=4) ; **, p <0.05 when rosuvastatin treated Ren2 rats 
(Ren2-RSV) (n=4) or SD (SD-RSV) (n=4) are compared to age-matched controls. 
 
Figure S3: Rosuvastatin improves Oxidative Stress.  (A) 3-nitrotyrosine 
immunostaining as a marker of peroxynitrite formation in the transgenic Ren2 rat.  (B) 
Grey scale intensity measures of panel A.  (scale bar = 50 µM) *, p <0.05 when Ren2 
controls (Ren2-C) (n=4) are compared to age-matched Sprague-Dawley controls (SD-C) 
(n=4) ; **, p <0.05 when rosuvastatin treated Ren2 rats (Ren2-RSV) (n=4) or SD (SD-
RSV) (n=4) are compared to age-matched controls. (C) Dihydroethidium immunostaining 
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as a marker of superoxide anion formation in podocyte cell culture (n=4).  *, p<0.05 
when compared to control; **, p <0.05 when compared to angiotensin II stimulation 
alone. 
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Figure S2 
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